Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





Precision Medicine for Early Prostate Cancer: Integrating Biological and Patient Complexity Variables to Predict Treatment Response

Cancer
Edward Uchio
Prostate

Study Description

Replicate/validate the risk prediction model developed for the CEASAR study in a

more diverse patient population to assess generalizability of the model, comparing patients who

receive radical prostatectomy, radiation therapy, or active surveillance for their prostate cancer

Eligibility

Adult males aged 18 years to 79 years old

Diagnosis of prostate cancer, clinical stage T1 or T2, with no evidence of metastasis

PSA less than 50 ng/mL

Not previously undergone any treatment for prostate cancer

Diagnosis of prostate cancer less than 6 months before baseline visit

Minors and women were specifically excluded because prostate cancer does not affect these

populations.

A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.